The sequence of the peptide is based on the complementarity determining region
1 (CDR1) of a pathogenic human anti-DNA monoclonal antibody (mAb) that bears the 16/6 idiotype (16/6 Id)1.
The subject of this patent is his discovery that the TCR second complementarity determining region
(CDR2) can provide vaccines having greater selectivity and potency for the larger numbers of patients.
An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions
Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions
(CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided.
The antibodies can be made by grafting of the complementarity determining regions
of mouse monoclonal antibody to human 4-1BB to the remaining portions of a human antibody and by making further amino acid replacements.